Vanguard Group Inc Sera Prognostics, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Sera Prognostics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 896,163 shares of SERA stock, worth $5.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

896,163

Previous 909,502 1.47%

Holding current value

$5.31 Million

Previous $5.44 Million 49.96%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$5.05 - $10.0 $67,361 - $133,390	-13,339 Reduced 1.47%	896,163 $8.16 Million
Q4 2023 Feb 14, 2024	BUY	$1.65 - $6.85 $202,471 - $840,563	122,710 Added 15.6%	909,502 $5.44 Million
Q3 2023 Nov 14, 2023	BUY	$1.55 - $3.34 $20,714 - $44,635	13,364 Added 1.73%	786,792 $1.46 Million
Q2 2023 Aug 14, 2023	BUY	$3.0 - $3.98 $41,484 - $55,035	13,828 Added 1.82%	773,428 $2.54 Million
Q1 2023 May 15, 2023	BUY	$1.19 - $4.25 $650,982 - $2.32 Million	547,044 Added 257.36%	759,600 $2.91 Million

Q4 2022 Feb 10, 2023	BUY	$1.16 - $1.61 $671 - $932	579 Added 0.27%	212,556 $267,000
Q3 2022 Nov 14, 2022	BUY	$1.6 - $2.71 $33,862 - $57,354	21,164 Added 11.09%	211,977 $339,000
Q2 2022 Aug 12, 2022	BUY	$1.2 - $3.62 $3,223 - $9,723	2,686 Added 1.43%	190,813 $313,000
Q1 2022 May 13, 2022	BUY	$2.96 - $8.8 $36,479 - $108,451	12,324 Added 7.01%	188,127 $713,000
Q4 2021 Feb 14, 2022	BUY	$6.87 - $11.41 $431,071 - $715,943	62,747 Added 55.5%	175,803 $1.21 Million
Q3 2021 Nov 12, 2021	BUY	$7.9 - $13.04 $893,142 - $1.47 Million	113,056 New	113,056 $1.26 Million

Others Institutions Holding SERA

# of Institutions

Shares Held

14.9M

Call Options Held

Put Options Held

View Full List

About SERA PROGNOSTICS, INC.

Ticker SERA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 29,596,900
Market Cap $175M
Description
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product ...

More about SERA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Sera Prognostics, Inc. Transaction History